Exclusive: U.S. prosecutors add China bribery allegations to GlaxoSmithKline probe - (Fidelity via NewsPoints Desk)

  • A GlaxoSmithKline spokesman confirmed Friday that US prosecutors are investigating the company for anti-bribery violations in China, as reported Fidelity.
  • According to a source, the US Department of Justice expanded a probe of GlaxoSmithKline's practices in other countries to include allegations of bribery in China.
  • Chinese authorities revealed in July that four GlaxoSmithKline executives were detained on allegations that the company funnelled up to 3 billion yuan in kickbacks to doctors and officials in the country.
  • US officials are investigating whether GlaxoSmithKline violated the Foreign Corrupt Practices act, which forbids companies based in the US or those whose stocks are listed on a US stock exchange from engaging in bribery
  • GlaxoSmithKline acknowledged that some of its employees in China may have engaged in bribery, but it denies that the company had any knowledge of the activity.
  • "Since the investigation in China began we have proactively reached out to relevant regulators," remarked GlaxoSmithKline spokesman David Mawdsley, adding "this includes the [US Department of Justice}, and we have been in an ongoing dialogue with them."

To read more NewsPoints articles, click here.